These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19587325)

  • 1. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
    Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of amyloid deposition in patients with mild cognitive impairment.
    Forsberg A; Engler H; Almkvist O; Blomquist G; Hagman G; Wall A; Ringheim A; Långström B; Nordberg A
    Neurobiol Aging; 2008 Oct; 29(10):1456-65. PubMed ID: 17499392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
    Raji CA; Becker JT; Tsopelas ND; Price JC; Mathis CA; Saxton JA; Lopresti BJ; Hoge JA; Ziolko SK; DeKosky ST; Klunk WE
    J Neurosci Methods; 2008 Jul; 172(2):277-82. PubMed ID: 18582948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal assessment of amyloid-beta deposition in initially amyloid-negative non-demented individuals with [11C]-PIB PET imaging.
    Hatashita S; Wakebe D
    Medicine (Baltimore); 2021 Sep; 100(35):e27055. PubMed ID: 34477136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
    Nordberg A; Carter SF; Rinne J; Drzezga A; Brooks DJ; Vandenberghe R; Perani D; Forsberg A; Långström B; Scheinin N; Karrasch M; Någren K; Grimmer T; Miederer I; Edison P; Okello A; Van Laere K; Nelissen N; Vandenbulcke M; Garibotto V; Almkvist O; Kalbe E; Hinz R; Herholz K
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):104-14. PubMed ID: 22961445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study.
    Okello A; Edison P; Archer HA; Turkheimer FE; Kennedy J; Bullock R; Walker Z; Kennedy A; Fox N; Rossor M; Brooks DJ
    Neurology; 2009 Jan; 72(1):56-62. PubMed ID: 19122031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold.
    Ismail R; Parbo P; Hansen KV; Schaldemose JL; Dalby RB; Tietze A; Kjeldsen PL; la Cour SH; Qvist P; Gottrup H; Eskildsen SF; Brooks DJ
    J Neuroimaging; 2019 Jul; 29(4):499-505. PubMed ID: 31074062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
    Villemagne VL; Pike KE; Chételat G; Ellis KA; Mulligan RS; Bourgeat P; Ackermann U; Jones G; Szoeke C; Salvado O; Martins R; O'Keefe G; Mathis CA; Klunk WE; Ames D; Masters CL; Rowe CC
    Ann Neurol; 2011 Jan; 69(1):181-92. PubMed ID: 21280088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified method of 3D-SSP analysis for amyloid PET imaging using [¹¹C]BF-227.
    Kaneta T; Okamura N; Minoshima S; Furukawa K; Tashiro M; Furumoto S; Iwata R; Fukuda H; Takahashi S; Yanai K; Kudo Y; Arai H
    Ann Nucl Med; 2011 Dec; 25(10):732-9. PubMed ID: 21792587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.